Loading...
Loading...
Analysts at Baird downgraded Theravance Biopharma
TBPH from Neutral to Underperform.
The target price for Theravance Biopharma is set to $21.
Theravance Biopharma's shares surged 2.56% to close at $29.65 yesterday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
